Targeting other pathological hallmarks like mitochondrial dysfunction and aberrant aggregation of the protein alpha-synuclein, resulting in characteristic Lewy pathology, was successful in animal models of PD, but until now, not in clinical trials [8]. This evidence concerns the gene SNCA and Parkinson disease.